admin

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today its LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in studies conducted at the University of Georgia Center for Vaccines and Immunology.

Scientists at the University of Georgia working in conjunction with CEL-SCI’s scientific team conducted a challenge study in human(h) ACE2 receptor transgenic mice infected with a dose of SARS-CoV-2 (the causative agent of COVID-19 disease) virus sufficient to cause death in all animals within 8 days. This transgenic animal model is useful to study COVID-19 disease because the mice express the molecule that provides entry for the SARS-CoV-2 virus into human cells. Virus infection is optimized in this animal model providing an ideal system to determine vaccine induced immune protection or therapy against a SARS-CoV-2 infection of humans.

The effort to develop a COVID-19 vaccine is continuing to create new demand for life sciences space in Montgomery County, with one of the leading vaccine developers taking over a former industrial building and land previously planned for mixed-use development. 

Novavax, a biotech company that has received $2B in funding for its COVID-19 work, announced Monday it signed a 122K SF lease at 700 Quince Orchard Road in Gaithersburg. 

The Pinkney Innovation Complex for Science and Technology at Montgomery College (PIC MC) Combines Innovation and Education – a smart choice for co-location.

The BioHealth Capital Region has come to be known for its unique blend of Industry, Government, and Academia from Baltimore to Charlottesville. Unlike many of the other Biotech Hubs across the United States, the geographic spacing, which at times has been seen as a challenge in the region, has created new opportunities.

Image: https://biobuzz.io/

PASADENA, Calif., Dec. 1, 2020 /PRNewswire/ — Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, today announced that it has been recognized as the #1 real estate company in the world in the Global Real Estate Sustainability Benchmark (GRESB) 2020 Science & Technology sector for its leadership in championing sustainability initiatives that promote the health and well-being of its tenants and employees and enhance local communities. Alexandria also earned the #1 global ranking and a 5 Star Rating—the highest GRESB Rating—in its Diversified Listed Peer Group for its highly sustainable development work and green building initiatives, as well as an “A” disclosure score for the third consecutive year. GRESB is one of the leading global environmental, social and governance (ESG) benchmarks for real estate and infrastructure investments across the globe.

The University of Maryland, Baltimore (UMB) strives to support the entrepreneurial talents of its students, faculty, staff, and alumni as it works to improve the human condition and serve the public good.

To this end, the University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state with the $10 million Maryland Momentum Fund (MMF).

Pitch Perfect: The Art and Science of Communicating with Investors Before AND After Funding Communicating with investors before AND after funding is both an art and science. Learn best strategies at this truly informative webinar.

This free webinar is brought to you by the Society of Physician Entrepreneurs and the George Washington University Technology Commercialization Office.

Among the front-runners racing to deliver a Covid-19 shot, AstraZeneca PLC has the least vaccine experience. But it has promised the world the most doses—more than three billion.

The company has assembled an unprecedented network of manufacturing and distribution partners spanning the globe, complementing a series of deals with governments that have sought to lock in vaccine supplies for their countries.

Seven start-up companies and university research projects across a range of therapeutic areas and geographical locations form latest intake for life science incubator BioInnovation Institute

COPENHAGEN, Denmark, 2nd December – BioInnovation Institute (BII), a Novo Nordisk Foundation initiative incubating and accelerating world-class life science research, today identifies its latest cohort of program participants.  Comprising a pan-European spread of start-up companies and university research projects in countries including Denmark, Sweden and the UK, the seven ventures are developing revolutionary science across BII’s three sector specialised areas – therapeutics, bioindustrial and health tech.

Chevy Chase, MD – May 22, 2019 – New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the appointment of Scott Gottlieb, M.D., as a Special Partner on the firm’s healthcare investment team. Dr. Gottlieb was a Venture Partner at NEA from 2007 to 2017 before being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019.

Under Dr. Gottlieb’s leadership, the FDA advanced new policies for the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices; implemented new reforms to standardize drug and medical device reviews; and promoted policies to reduce death and disease from tobacco, improve food innovation and safety, promote better nutrition, and aggressively confront addiction crises.